Related Experiment Video
Updated: Aug 15, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
The global bioequivalence harmonisation initiative: Report of EUFEPS/AAPS third conference
Mehul Mehta1, Henning Blume2, Gerald Beuerle3
1U.S. Food and Drug Administration, MD, USA.
Abstract:
The European Federation of Pharmaceutical Sciences (EUFEPS) and American Association of Pharmaceutical Scientists (AAPS) have collaborated since 2015 to organize international conferences to support global harmonization of regulatory requirements for bioequivalence (BE) assessment. This collaboration has resulted in three Global Bioequivalence Harmonization Initiative (GBHI) workshops which provided a unique opportunity for scientists from academia, industry, and regulatory agencies to discuss current, complex BE issues. The 3rd GBHI workshop was held in April 2018 in Amsterdam/The Netherlands and covered the following topics: (a) the necessity of multiple-dose studies in BE testing; (b) BE of transdermal delivery systems, and (c) liposomal parenteral preparations. This report summarizes the extensive discussions that led to better understanding of the similarities and differences across the major regulatory agencies on these topics and paved the way for future international harmonization.
Related Concept Videos
Bioequivalence: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Measurement of Bioavailability: Pharmacodynamic Methods
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation
Bioequivalence of Drugs: Drugs with Multiple Indications

